Benefits
Muscle hypertrophy and lean mass gains
Human RCTs show phosphatidic acid supplementation (750 mg/day) combined with resistance training produces significantly greater increases in lean body mass compared to training alone. Studies show 50–100% greater lean mass gains vs. placebo groups performing identical training protocols.
Strength increases
PA supplementation significantly enhances strength development in trained individuals performing resistance exercise. Studies show greater 1RM improvements in squat and bench press compared to placebo, with effects most pronounced in experienced lifters where training-driven adaptations plateau.
mTOR-mediated muscle protein synthesis
PA is the first supplement identified to directly bind and activate mTORC1 (mechanistic target of rapamycin complex 1) — the master switch for muscle protein synthesis. This provides a mechanistic explanation for observed anabolic effects that distinguishes PA from supplements working through hormonal or nutritional pathways.
Body composition optimization
Beyond absolute lean mass, PA supplementation improves the ratio of lean mass to fat mass gained during resistance training phases, supporting more favorable body recomposition outcomes alongside training and adequate protein intake.
Mechanism of action
Direct mTORC1 activation via PLD pathway
Mechanical stress during resistance exercise activates phospholipase D (PLD), which converts membrane phosphatidylcholine to phosphatidic acid. PA then directly binds the FKBP12-rapamycin binding (FRB) domain of mTOR, activating mTORC1 and triggering ribosomal S6 kinase 1 (S6K1) phosphorylation — the proximal signal for muscle protein synthesis initiation.
Synergy with mechanical muscle loading
PA's anabolic effects require resistance exercise stimulus — it amplifies the mTOR response to mechanical loading rather than activating it independently. This exercise-dependency explains why PA is specifically effective in trained individuals performing progressive resistance training rather than in sedentary populations.
Myofibrillar protein synthesis enhancement
PA-mediated mTORC1 activation specifically enhances myofibrillar (contractile) protein synthesis in type II muscle fibers, increasing the synthesis of myosin heavy chain and actin — the proteins that directly contribute to muscle size and force production.
Clinical trials
Randomized, double-blind, placebo-controlled trial of Mediator® PA (750 mg/day) vs placebo in 28 resistance-trained men + 8-week resistance training program. Outcomes: lean body mass (DXA), squat 1RM. (Joy et al. 2014, Nutr Metab)
28 resistance-trained men. 8-week intervention.
PA group gained more lean body mass (~+2.4 kg vs +1.2 kg placebo) and showed greater squat 1RM improvement vs placebo. Critical caveat: small trial (n=28), industry-funded (Chemi Nutra); subsequent independent trials have been mixed — some negative. Effects haven't been consistently replicated.
Follow-up clinical trial of PA supplementation in trained men using identical protocol with biomarker analysis including muscle CSA via MRI. (J Sports Sci Med)
Resistance-trained men.
PA supplementation produced greater muscle cross-sectional area increases by MRI vs placebo. Industry-funded. Modest effect sizes. Independent replication mixed.